Paper Details

  1. Home
  2. Paper Details

Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation.

Author: Alarcon-OcegueraFelipe, Baiza-DuranLeopoldo, Beltran-LoustaunauMarco, Castaneda-HernandezGilberto, Cortez-GastelumMarco, Garcidueñas-MejiaJorge, Gomez-BastarPedro, GonzalezJaime R, Jimenez-RomanJesus, Korder-OrtegaVincent, OrtizMario, Paczka-ZapataJose, Quintana-HauJuan, Tornero-MontañoRuben, Torres-SeguraMarina, Velasco-GallegosGustavo

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A new latanoprost ophthalmic solution containing cyclodextrins was shown to be stable at temperatures up to 40 degrees C, compared to the innovator product which was only stable at 4 degrees C.
Paper Details　
Original Abstract of the Article :
Recently, a new latanoprost ophthalmic solution containing cyclodextrins was developed. The purpose of the present work was to compare the stability, clinical efficacy, and adverse effect profile of this formulation with the innovator product. The innovator formulation was stable at 4 degrees C but ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0091270006292626

データ提供：米国国立医学図書館（NLM）

Latanoprost: A New Formulation Emerges from the Sands of Glaucoma Treatment

This research compares the effectiveness and safety of two different latanoprost formulations used to treat glaucoma. It's like comparing two paths through a desert - both lead to the same destination, but one might be smoother and safer than the other. The researchers aimed to determine if a new formulation containing cyclodextrins offered any advantages over the original formulation. They were like explorers seeking out a new path through the desert, hoping to find a route that was easier and less treacherous.

Equivalent Efficacy, Improved Stability: A New Oasis in Glaucoma Treatment

This research found that both formulations were equally effective in reducing intraocular pressure, the primary goal of glaucoma treatment. However, the new formulation containing cyclodextrins exhibited significantly improved stability, meaning it could withstand higher temperatures. This is like finding a spring in the desert that can be used to create a more durable source of water. The new formulation offers a more reliable and robust treatment option for patients with glaucoma.

Navigating the Desert of Glaucoma

This research highlights the ongoing quest to find better and safer treatments for glaucoma. It's like finding a new oasis in the desert, offering a more reliable and resilient source of water. The new formulation of latanoprost offers a promising option for patients, but further research is needed to understand its long-term effects and to explore other potential innovations in glaucoma treatment.

Dr.Camel's Conclusion

This study provides a valuable comparison of two different latanoprost formulations, showcasing the benefits of the new cyclodextrin-containing formulation. It's like finding a more stable and reliable oasis in the desert of glaucoma treatment! This research highlights the importance of innovation in developing better and safer treatments for patients with glaucoma.

Date :
  1. Date Completed 2007-03-01
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17192510

DOI: Digital Object Identifier

10.1177/0091270006292626

Related Literature

Article Analysis
・Effects of latanoprost ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.